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Abstract
Although abdominal surgery is an established risk factor for invasive candidiasis, the precise role of antifungal prophylaxis in these
patients is not agreed upon. In 2007, ﬂuconazole was added to the prophylactic antibiotic treatment for patients with gastrointestinal
tract perforations or reoperation after colorectal surgery in two university hospitals in Copenhagen. Changes in candidaemia rates asso-
ciated with this intervention were examined and potential interfering factors evaluated. Rates and clinical characteristics of candidaemias
and other blood stream infections (BSIs) in abdominal surgery patients were compared before (1 January 2006 to 30 June 2007) and
after the intervention (1 January 2008 to 30 June 2009). The departments’ activity was assessed by number of bed-days, admissions and
surgical procedures, and the consumption of antifungals was analysed. The candidaemia rate decreased from 1.5/1000 admissions in the
pre-intervention to 0.3/1000 admissions in the post-intervention period (p 0.002). Numbers of BSIs and bed-days remained stable, and
numbers of admissions and surgical procedures performed increased during the study period. Fluconazole consumption in the two
abdominal surgery departments increased from 4.6 to 12.2 deﬁned daily doses per 100 bed-days (p <0.001), and 3.2 to 5.0 (p 0.01),
respectively, but remained unchanged in the intensive care units. We could not detect any increase in ﬂuconazole-resistant strains (14/
29 pre- and 2/7 post-intervention, p 0.43). The introduction of ﬂuconazole prophylaxis was followed by a signiﬁcantly decreased candi-
daemia rate. However, the observational study design does not allow conclusions regarding causality. No increase in resistance was
detected, but follow-up was short and continuing surveillance is needed.
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Introduction
Invasive Candida infections are frequently observed in critically
ill patients and are associated with high mortality and costs
[1–4]. The source of candidaemia can frequently be related to
the gastrointestinal system, and abdominal surgery is an impor-
tant risk factor [2,5]. Diagnosis is often dependant on cultures
and therefore delayed. Early treatment is crucial, because
delayed treatment is associated with increased mortality [6,7].
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Prophylactic antifungal therapy in abdominal surgery and
critically ill patients has been shown to reduce rates of inva-
sive Candida infections in several randomized controlled trials
[8–10]. However, other studies failed to detect a signiﬁcant
effect [11–13]. Inclusion criteria and antifungal regimen in
these studies varied substantially and meta-analyses reached
conﬂicting results regarding the effect on mortality [14–16].
Another approach, pre-emptive therapy based on a Candida
colonization index has been shown to reduce Candida infec-
tions [17], but is labour intensive. Finally, empiric therapy in
post-operative and intensive care unit (ICU) patients has
been studied showing differing results [18,19]. Current guide-
lines summarize these conﬂicting results by acknowledging
the role of prophylactic and empiric antifungal therapy, while
exact indications remain undetermined [20,21]. Recently
published guidelines for the management of intra-abdominal
infections, however, concentrate on antifungal therapy for
culture-proven severe or healthcare-associated infections
[22]. The presence of Candida in intra-abdominal specimens
is associated with increased mortality, at least in certain
subgroups of patients [13,23].
There is a general concern about increased selection pres-
sure associated with widespread use of antifungals and ﬂuco-
nazole exposure is a risk factor for non-albicans candidaemia
in the ICU [24].
The incidence of candidaemia in Denmark has been higher
than in neighbouring countries, with approximately half of the
patients having undergone gastrointestinal surgery ([25] and
Arendrup MC et al., 18th European Congress of Clinical
Microbiology and Infectious Diseases 2008, poster 1576). The
proportion of isolates with reduced ﬂuconazole susceptibility
is unusually high and increasing in Denmark [25]. An interven-
tion was made in 2007 in two university hospitals in Copenha-
gen. Fluconazole was added to the prophylactic antibiotic
treatment recommendations for patients with gastrointestinal
tract perforation or reoperation after colorectal surgery.
The aim of this study was to assess candidaemia rates
before and after this intervention and to evaluate potential
interfering factors.
Materials and Methods
Setting
The Copenhagen University Hospitals in Hvidovre (hospital
A) and Bispebjerg (hospital B) were served by the Depart-
ment of Clinical Microbiology Copenhagen University Hospi-
tal, Hvidovre.
The abdominal surgery department at hospital A had 5421
admissions in 2008 and performed 2545 surgical procedures,
serving 175 000 inhabitants, while the department in hospital
B had 7393 admissions and performed 2593 surgical proce-
dures, serving 340 000 inhabitants. Both departments serve as
community hospitals, performing elective and acute surgery.
The corresponding ICUs had 86 abdominal surgery admis-
sions out of 533 total admissions in 2008 (hospital A) and 92
out of 444 (hospital B). Routine surveillance cultures were
not used.
Microbiological methods
The blood culture system BacT/ALERT (bioMe´rieux, Marcy
l¢Etoile France) was used. Candida species identiﬁcation was
based on colony morphology on CHROMagar (Becton Dick-
inson, Heidelberg, Germany) and the VITEK 2 system (bio-
Me´rieux, Marcy l¢Etoile France). Susceptibility testing was
evaluated by the VITEK 2 system and Etest (AB bioMe´rieux,
Solna Sweden). All Candida isolates from blood cultures were
referred to the Danish reference laboratory, where species
identiﬁcation and susceptibility testing according to the Euro-
pean Committee on Antimicrobial Susceptibility Testing (EU-
CAST) methods were performed as part of the semi-
national surveillance programme as previously described
[25,26]. For the interpretation of the minimal inhibitory con-
centration (MIC), the following breakpoints (S£/R>) were
used. Fluconazole species-related breakpoints: C. albicans and
C. tropicalis, 2/4 mg/L; C. glabrata and C. krusei: no break-
points, these species are considered intrinsically non-suscep-
tible and resistant, respectively [27]; Amphotericin B: 1/
1 mg/L; Caspofungin: 2/2 mg/L [28].
The intervention
The guidelines for antimicrobial treatment were issued in
cooperation with the Department of Clinical Microbiology
and the hospitals’ therapeutic and drug committees. In July
2007, these guidelines were changed to include ﬂuconazole
400 mg intravenously once daily for patients with gastro-
intestinal tract perforation (except for perforated appendici-
tis) or reoperation after colorectal procedures. The
guidelines were the same for both hospitals, except that in
hospital A all patients with peptic ulcer perforation received
ﬂuconazole prophylaxis, while these patients in hospital B
only received ﬂuconazole in case of delayed operation and
severe peritoneal inﬂammation.
The treatment was prescribed as a ﬁxed combination in
the electronic drug prescription system for 3 days. Thereaf-
ter, need for further treatment was to be re-evaluated. At
the same time, the recommended antibiotic regimen was
changed from ampicillin or cefuroxime, with gentamicin and
metronidazole, to piperacilline-tazobactam and metronida-
zole, eventually supplemented with ciproﬂoxacin.
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These recommendations were implemented in the second
half-year of 2007. Consequently, we compared for statistical
analysis the periods 1 January 2006 through to 30 June 2007
and 1 January 2008 through to 30 June 2009.
Case deﬁnition and collection of data
All candidaemia episodes in abdominal surgery patients in the
surgical departments or ICUs from 1 January 2006 through
to 30 June 2009 were investigated and patient charts
reviewed. Patients were excluded if transferred after surgery
at other hospitals <48 h before the positive blood culture
was taken (two patients; one pre- and one post-interven-
tion). Cases with necrotizing pancreatitis were excluded, as
these patients in hospital A are mainly cared for by the med-
ical gastroenterologists and treatment standards have sub-
stantially changed during the study period (ﬁve patients;
three pre-intervention, one in the second half-year 2007,
one post-intervention).
Infections were classiﬁed as nosocomial, if diagnosed
>48 h after admission and no signs of infection had been
present at admission.
All blood stream infections (BSI) were registered prospec-
tively in the laboratory database system including clinical
information. Recurrence with the same pathogen and focus
within 30 days was deﬁned as one episode.
Numbers of bed-days and admissions were collected from
the hospitals’ administrative systems. Numbers of surgical
procedures were assessed by the departments’ electronic
systems; endoscopic procedures were excluded.
Consumption data for antimicrobial agents was collected
from the hospital pharmacy database of drug sales.
Statistical analysis
Numerical data were compared using the Mann–Whitney
U-test and proportions were compared using Fisher’s exact
test. Analysis was performed with GRAPHPAD INSTAT (Version
3.05; GraphPad Software Inc., La Jolla, CA, USA) and two-
tailed p-values <0.05 were considered signiﬁcant.
Ethical considerations
The study was conducted according to the guidelines of the
regional scientiﬁc ethics committee for use of clinical and
laboratory data and approved by the Danish Data Protection
Agency (Record no. 2007-41-0627).
Results
From 1 January 2006 through to 30 June 2009, candidaemia
was diagnosed in 40 abdominal surgery patients, declining
signiﬁcantly from 27 candidaemia patients (1.5/1000 admis-
sions and 42.7/100 000 bed-days) in the pre-intervention
period to seven patients (0.3/1000 admissions, 10.3/100 000
bed-days) in the post-intervention period (p 0.002, Fig. 1 and
Table 1). Six patients were diagnosed from 1 July through to
31 December 2007 while the new guidelines were imple-
mented (Fig. 1). The characteristics of the 34 patients in the
pre- and post-intervention period are shown in Table 2.
The number of BSIs in abdominal surgery patients did not
change (p 0.51). While the increase in the number of
bed-days was non-signiﬁcant (p 0.13), admissions increased
signiﬁcantly by 18% (p 0.02). There was a signiﬁcant increase
in surgical procedures with opening of the gastrointestinal
tract by 13%, (p 0.02). In hospital A, laparoscopic procedures
accounted for 8% of these procedures in the pre-interven-
tion period and for 24% in the post-intervention period. In
hospital B, the proportion of laparoscopic procedures
increased from 41% to 52% (Table 1).
Fluconazole consumption increased signiﬁcantly in the
abdominal surgery departments while the increase in the
ICUs was non-signiﬁcant (Table 3).
The consumption of antibacterial agents, amphotericin B
and caspofungin was stable apart from an increase in caspo-
fungin use in the ICU in hospital B and a low, but emerging
caspofungin use in the surgical department in hospital B
(Table 3).
The median age of the candidaemia patients was 73 years
(range 32–86). Eighteen (53%) of the 34 patients were
female. The crude 30-day mortality was 62% (21/34); 67%
(18/27) in the pre-intervention period and 43% (3/7) in the
post-intervention period (p 0.39, pre- vs. post-intervention).
Twenty-nine (85%) patients had nosocomial infections and
ﬁve (15%) community-acquired infections (all in the pre-
intervention period). Three of these ﬁve patients had a pep-
tic ulcer, one had a colon perforation and one presented
with upper gastrointestinal bleeding, but died before further
diagnosis.
In 20 of 27 patients in the pre-intervention period and
three of seven patients in the post-intervention period, the
gastrointestinal tract had been opened, either through spon-
taneous perforation or during a surgical procedure.
Two patients had mixed candidaemia, both in the pre-inter-
vention period (C. glabrata/C. krusei and C. albicans/C. glabrata,
respectively). Of the 36 isolates from the pre- and post-inter-
vention periods, 19 (53%) were C. albicans, 13 (36%) were
C. glabrata, two (6%) were C. krusei and two (6%) were
C. tropicalis. The proportion of non-albicans strains did not
differ between the pre- (14/29) and post-intervention period
(3/7; p 1.00). Twenty of the 36 isolates (56%) were ﬂuconaz-
ole susceptible (Table 4). All isolates were caspofungin
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susceptible. Thirty-ﬁve isolates were amphotericin B suscepti-
ble, but one C. tropicalis isolate in 2008 had an MIC for
amphotericin B above the breakpoint (MIC = 2 mg/L).
Discussion
We found a decreasing rate of candidaemia in abdominal sur-
gery patients at two university hospitals in the Copenhagen
area after the introduction of ﬂuconazole prophylaxis. At the
same time, numbers of bacteraemia episodes remained
unchanged. Numbers of bed-days were stable, while admis-
sions increased, reﬂecting the trend towards shorter hospital
stays.
We further assessed surgical procedures performed and
distinguished them into those with an opening of the gas-
trointestinal tract, considering that as a major risk factor for
candidaemia, and those without. The number of procedures
FIG. 1.Quarterly numbers of candidaemia
patients, episodes of blood stream infections,
admissions, surgical procedures and ﬂucona-
zole consumption. Patients with candidaemia,
BSI episodes and admissions in ICUs include
only abdominal surgery patients. Fluconazole
consumption in ICUs was calculated for all
patients. Q, quartal; BSI, blood stream infec-
tion; ICU, intensive care unit; DDD, deﬁned
daily doses.
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with an opening of the gastrointestinal tract increased,
while the number of procedures without remained
unchanged. Thus, we have found a decreasing candidaemia
rate, while the departments’ activity was at least stable, if
not increasing.
We pooled data from two different hospitals, because
they have comparable activity and the same intervention was
made. However, three differences have to be discussed.
Firstly, there was a decrease in open surgery involving an
opening of the gastrointestinal tract in hospital A, while
laparoscopic procedures increased. Thus, lower complication
rates of laparoscopic procedures could be an explanation for
the decreasing candidaemia rate. However, as in hospital B
open procedures remained unchanged and laparoscopic pro-
cedures increased additionally, this explanation is unlikely.
Secondly, one could conversely assume that the higher
candidaemia rate in hospital B in the pre-intervention period
was a consequence of the higher proportion of laparoscopic
procedures. This is unlikely, as none of the 18 candidaemic
patients in hospital B had undergone a laparoscopic proce-
dure.
Finally, the baseline ﬂuconazole consumption and its
increase in the surgery department in hospital A were
remarkably higher than in hospital B. In hospital A, the
abdominal surgery and medical gastroenterology department
is one unit, making interpretation of consumption data difﬁ-
cult. More restrictive use of ﬂuconazole prophylaxis for pep-
tic ulcer perforation in hospital B may be one explanation.
Yet more important, seems to be the fact, that hospital A
evolved as a referral centre for necrotizing pancreatitis
patients who frequently receive ﬂuconazole for a long time.
However, as data on individual indications for ﬂuconazole
use are not available, we cannot entirely rule out a more lib-
eral use of ﬂuconazole in hospital A.
When examining hospital B alone (where the interpreta-
tion of consumption data is more straightforward and surgi-
cal activity clearly increased), the candidaemia rate still
decreased signiﬁcantly from 1.7 to 0.2/1000 admissions. An
TABLE 1. Number of patients with candidaemia, episodes of blood stream infections, bed-days, admissions and surgical proce-
dures performed
Pre-intervention period Post-intervention period
Change of
total no. (%) paTotal no.
Monthly
median; range Total no.
Monthly
median; range
Patients with candidaemiab
Hospital A 9 0.5; 0–1 4 0; 0–1 )56 0.15
Hospital B 18 1; 0–2 3 0; 0–1 )83 0.002
Total 27 2; 0–3 7 0; 0–1 )74 0.002
BSI episodesb
Hospital A 131 7; 2–16 128 7; 3–13 )2 0.92
Hospital B 125 7; 3–14 117 6.5; 3–13 )6 0.67
Total 256 14; 9–21 245 13; 7–22 )4 0.51
Bed-daysb
Hospital A 32 142 1788; 1526–2106 34 777 2014; 1530–2349 +8 0.07
Hospital B 31 091 1748; 1315–2054 32 973 1738; 1455–2225 +6 0.22
Total 63 233 3494; 3078–4044 67 750 3779; 3186–4406 +7 0.13
Admissionsb
Hospital A 7713 414; 368–490 9269 543; 317–703 +20 0.04
Hospital B 10 514 604; 459–709 12 235 696; 500–881 +16 0.01
Total 18 227 1025; 843–1175 21 504 1218; 817–1584 +18 0.02
Surgical proceduresc
Procedures with opening of gastrointestinal tract
a. Open surgery
Hospital A 1237 71; 46–82 1088 60; 49–87 )12 0.009
Hospital B 558 31; 14–40 560 31; 26–42 ±0 0.87
Total 1795 99; 70–121 1648 89; 79–113 )8 0.04
b. Laparoscopy
Hospital A 113 5; 2–17 345 21; 4–45 +205 <0.001
Hospital B 388 22; 13–31 612 34; 19–49 +58 <0.001
Total 501 28; 18–40 957 55; 28–94 +91 <0.001
a+b
Hospital A 1350 75; 59–92 1433 81; 53–132 +6 0.31
Hospital B 946 52; 34–71 1172 67; 47–76 +24 <0.001
Total 2296 125; 110–157 2605 148; 110–207 +13 0.02
c. Procedures without opening of the gastrointestinal tract
Hospital A 2880 159; 95–196 2743 154; 79–210 )5 0.51
Hospital B 2973 176; 73–216 3040 183; 73–251 +2 0.58
Total 5853 339; 179–411 5783 346; 152–451 )1 0.82
aMann–Whitney U-test comparing monthly numbers in the pre- and post-intervention periods.
bPatients with candidaemia, blood stream infection (BSI) episodes, bed-days and admissions include abdominal surgery patients in the surgical departments and intensive care
units.
cSurgical procedures were classiﬁed into (a) open surgery involving an opening of the gastrointestinal tract, (b) laparoscopic-assisted surgery involving an opening of the gas-
trointestinal tract, and (c) procedures without opening of the gastrointestinal tract.
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increase in ﬂuconazole consumption from 3.2 to 5.0 DDD
per 100 bed-days seems to be an acceptable price.
Previous studies mainly focused on ICU patients with
inclusion criteria related to the length of ICU stay or need
for mechanical ventilation [8,10]. However, about half of the
candidaemic patients in this study were diagnosed outside
the ICU. We chose to focus on the gut as the source of can-
didaemia instead of measures for critical illness. In a random-
ized, placebo-controlled study, ﬂuconazole prophylaxis
effectively prevented invasive candidiasis in abdominal surgery
patients with recurrent gastrointestinal perforation or anas-
tomotic leakage [9]. We chose wider inclusion criteria and
our approach seems to be promising. The gastrointestinal
tract had been opened through a spontaneous perforation
or during a surgical procedure in the majority of candidaemic
patients in this study, highlighting that our guidelines target
an appropriate risk group.
The drawback of antifungal prophylaxis could be an
increased use of antifungals and potential selection of resis-
tance. A systematic review suggested an increasing risk for
colonization with strains with decreased ﬂuconazole suscep-
tibility and non-albicans strains under ﬂuconazole prophylaxis
[29]. That review comprised heterogeneous patient popula-
tions and treatment durations and the included studies in
abdominal surgery and surgical ICU patients did not ﬁnd any
signiﬁcant emergence of resistance [8–10]. We did not
TABLE 2. Characteristics of patients with candidaemia
Pre-intervention period Post-intervention period
Peptic ulcer
No. of patients 5a 0
Hospital 2 A; 3 B
Age (years: median; range) 65; 47–78
Sexb 3 m; 2 f
Days from admission to candidaemia (median; range) 2; 1–6
No. of patients treated with antifungals £14 days before candidaemia episode 0
No. of patients dead at day 30 3
Other intestinal perforation
No. of patients (small bowel; colon) 8
(4; 4)
0
Hospital 3 A; 5 B
Age (years: median; range) 68; 32–80
Sexb 4 m; 4 f
Days from admission to candidaemia (median; range) 11; 3–21
No. of patients treated with antifungals £14 days before candidaemia episode 2c
No. of patients dead at day 30 6
Complication after operation for colorectal cancer
No. of patients (ileus; anastomotic leakage; other) 6
(2; 2; 2)
1
(0; 1; 0)
Hospital 3 A; 3 B 1 B
Age (years: median; range) 77; 61–86 52
Sexb 5 m; 1 f 1 m
Days from admission to candidaemia (median; range) 26; 7–34 7
No. of patients treated with antifungals £14 days before candidaemia episode 0 1d
No. of patients dead at day 30 4 0
Other
No. of patients 8 6
Hospital 1 A; 7 B 4 A; 2 B
Age (years: median; range) 71; 56–84 76; 46–84
Sexb 2 m; 6 f 1 m; 5 f
Days from admission to candidaemia (median; range) 21; 1–80 19; 4–41
No. of patients treated with antifungals £14 days before candidaemia episode 3e 1f
No. of patients dead at day 30 5 3
Diagnosisg Upper gastrointestinal bleeding
Small bowel obstruction
Colectomy for pancolitis
Pseudo-obstruction after trauma
Small bowel ﬁstula
Inoperable pancreatic cancer
PN for duodenal stenosis, CVC-inf.
Colorectal cancer, CVC-inf.
Paralytic ileus after coloscopy
Incarcerated ventral hernia
Hemicolectomy after trauma
Colonic haemorrhage
Inoperable diaphragmatic hernia
PN for short bowel syndrome, CVC-inf.
Total no. of patients 27 7
aFour underwent operation for perforation, one for bleeding.
bm, male; f, female.
cOne patient had been treated empirically with ﬂuconazole for 8 days and had candidaemia with C. glabrata (MIC for ﬂuconazole >16 mg/L). One patient treated with ﬂuco-
nazole and subsequently caspofungin for 7 days in all (because of ﬂuconazole-resistant Candida cultured earlier from intra-abdominal specimen) had an intra-abdominal abscess
and candidaemia with ﬂuconazole-sensitive C. albicans and improved after surgical drainage.
dProphylaxis according to guidelines started 2 days before positive blood culture with C. krusei (MIC for ﬂuconazole >16 mg/L).
ePatient with small bowel obstruction had been treated with ﬂuconazole for positive cultures from respiratory sample, 2 days before candidaemia episode with ﬂuconazole-
sensitive C. albicans. Patient with pseudo-obstruction after trauma had been treated with ﬂuconazole as part of an empirical abdominal regime at another hospital at transfer-
ral 8 days before candidaemia episode with C. glabrata (MIC for ﬂuconazole >16 mg/L). Patient with small bowel ﬁstula had been treated with low-dose ﬂuconazole (50 mg
daily) for Candida oesophagitis for 10 days before candidaemia episode with ﬂuconazole-sensitive C. albicans.
fPatient treated empirically with ﬂuconazole 8 days after hemicolectomy after trauma and 3 days before candidaemia episode with ﬂuconazole-sensitive C. albicans.
gPN, parenteral nutrition; CVC-inf., central venous catheter infection.
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observe an increase in either number or proportion of ﬂuco-
nazole-resistant strains, but the 18-month follow-up period
might be too short and patient numbers too small. The high
baseline proportion of ﬂuconazole-resistant isolates is
another possible reason why further increase in resistance
was not detectable. Continuing surveillance is important.
However, the relatively short duration of our regimen rec-
ommendations might reduce the risk of selecting resistance.
We used an initial 3-day regimen, while most other trials
used treatment for 14 days or until ICU discharge [8,10,17].
Interestingly, we have not seen any C. glabrata isolates
after the introduction of ﬂuconazole prophylaxis, which
might indicate that the prophylactic dose used is sufﬁcient to
prevent infection with this species, despite higher MICs.
However, our ﬁndings are in contrast to the ﬁndings of Swo-
boda et al. [30], who found an increased proportion of
C. glabrata after the introduction of ﬂuconazole prophylaxis
in a surgical ICU.
A limitation of our study is the observational study design.
A change in the antibiotic regime was made at the same
time. However, as this change was towards a broader spec-
trum, we do not believe that it has affected our outcome.
We do not have information about the number of patients
matching our indication criteria for prophylaxis (the ‘target
group’), nor for those receiving prophylaxis, the actual
duration of treatment and the clinical outcome. We are
therefore not able to calculate the mortality in the target
group or a number needed to treat.
Because of the study design, no conclusion regarding cau-
sality can be drawn. However, the majority of the 27 candi-
daemia patients in the pre-intervention period met
indications for the later introduced ﬂuconazole prophylaxis.
In contrast, the seven patients in the post-intervention per-
iod form a heterogeneous group, and in most patients pro-
phylaxis was not indicated according to our guidelines
(Table 2). This may suggest that antifungal prophylaxis effec-
tively prevented candidaemia in the target group.
In conclusion, this observational study has shown a
decreasing candidaemia rate after the introduction of pro-
phylactic antifungal therapy for patients with gastrointestinal
tract perforation or reoperation after colorectal surgery.
TABLE 3. Consumption of antifun-
gal and antibacterial agents
Total DDDa; DDD per 100 bed-days
Pre-intervention Post-intervention Change (%) pb
Fluconazole
Hospital A, Surgeryc 1449; 4.6 4126; 12.2 +185; +163 <0.001; <0.001
Hospital A, ICUd 1884; 67.2 2578; 81.2 +37; +21 0.14; 0.37
Hospital B, Surgery 956; 3.2 1597; 5.0 +67; +57 0.006; 0.01
Hospital B, ICUd 1882; 77.5 2195; 79.5 +17; +3 0.38; 0.96
Amphotericin B
Hospital A, Surgeryc 272; 0.87 271; 0.80 ±0; )8 0.84; 0.81
Hospital A, ICUd 229; 8.1 331; 10.4 +45; +28 0.15; 0.17
Hospital B, Surgery 77; 0.25 157; 0.49 +105; +92 0.87; 0.86
Hospital B, ICUd 305; 12.6 427; 15.5 +40; +23 0.53; 0.67
Caspofungin
Hospital A, Surgeryc 73; 0.23 60; 0.18 )18; )24 0.53; 0.43
Hospital A, ICUd 112; 4.0 71; 2.2 )37; )44 0.69; 0.60
Hospital B, Surgery 0; 0 33; 0.10 NA NA
Hospital B, ICUd 76; 3.1 162; 5.9 +114; +88 0.03; 0.05
Antibacterial agents
Hospital A, Surgeryc 31 642; 101.4 32 468; 96.2 +3; )5 0.45; 0.44
Hospital A, ICUd 6000; 213.9 7328; 230.9 +22; +8 0.02; 0.10
Hospital B, Surgery 21 284; 70.4 25 047; 77.7 +18; +10 0.07; 0.22
Hospital B, ICUd 5888; 242.5 7048; 255.2 +20; +5 0.03; 0.30
NA, not applicable.
aDDD: deﬁned daily doses (ﬂuconazole, 200 mg; amphotericin B, 35 mg; caspofungin, 50 mg).
bMann–Whitney U-test comparing monthly numbers in the pre- and post-intervention period.
cDue to administrative reasons, ﬁgures for the surgical department in hospital A include partly medical patients.
dFor the intensive care units (ICUs), drug consumption and admissions are calculated for all patients, not only
abdominal surgery patients.
TABLE 4. Species distribution and susceptibility pattern
Fluconazole susceptibility
Pre-intervention Post-interven-
tion
S I R S I R
Species with interpretable EUCAST
breakpoints
C. albicans 15 4
C. tropicalis 1 1
Species with intrinsic elevated ﬂuconazole
MICs
C. glabrata 13 0
C. krusei 1 1
Proportion of
ﬂuconazole-susceptible isolatesa
15/29 5/7
Proportion of non-albicans isolatesb 14/29 3/7
S, susceptible; I, intermediate; R, resistant; EUCAST, European Committee on
Antimicrobial Susceptibility Testing; MIC, minimal inhibitory concentration.
aPre-intervention vs. post-intervention period: p 0.43.
bPre-intervention vs. post-intervention period: p 1.00.
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The deﬁnition of our inclusion criteria was practical and
simple. No increase in resistant strains was observed, which
could be due to methodological limitations, and close long-
term surveillance will be important. Further, randomized and
controlled trials are warranted to conﬁrm our indirect data,
before this approach can be applied to other settings.
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